A trial of VAL 083 in patients with non-small cell lung cancer

Trial Profile

A trial of VAL 083 in patients with non-small cell lung cancer

Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2015

At a glance

  • Drugs Dianhydrogalactitol (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Del Mar Pharmaceuticals; Guangxi Wuzhou Pharmaceutical
  • Most Recent Events

    • 02 Sep 2015 According to a DelMar pharmaceuticals media release, details of this trial will be presented at the 16th World Conference on Lung Cancer.
    • 15 Jun 2015 This study will be covered in a presentation by DelMar Pharmaceuticals at The World NSCLC Summit, according to a company media release.
    • 09 Oct 2014 Following successful in vivo studies of VAL 083 in models of NSCLC, DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals are expecting to conduct a clinical trial of VAL 083 in patients in China, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top